Skip to main content
. 2020 Apr 30;21(1):242–266. doi: 10.1080/14686996.2020.1748520

Figure 22.

Figure 22.

(a–d) In vivo biocompatibility of HA/SF-5% (black arrows denote lymphocytes, eosin and haematoxylin staining). (e–h) Increment of lymphocytes at the implantation site between control and experimental groups [187]